For the latest updates on our ongoing response to COVID-19, please click here.

PSC PACE Program

PSC PACE Program - PrimAry Sclerosing Cholangitis Epidemiology Program

Primary sclerosing cholangitis (PSC) is a rare, chronic cholestatic disease that primarily affects the bile ducts and the liver. PSC can be progressive and often lead to end stage liver failure. Patients with PSC have increased risk for cirrhosis, various types of cancer (i.e. cholangiocarcinoma) and the need for liver transplant. Currently, there is no known cure for PSC and the median survival for PSC patients is around 10-12 years after diagnosis. The overall incidence of PSC is estimated to be 1 per 100,000 person years. However, the epidemiology of PSC in general population remains unclear.

In an effort to further understand PSC epidemiology and patient outcomes from around the world, the Gilead Medical Affairs team is launching the PrimAry Sclerosing Cholangitis Epidemiology Program (PACE). The PSC PACE program will support individual projects of no more than $150,000 USD or equivalent sum. It is Gilead’s intent to support up to 5 well-defined projects.

Successful projects should demonstrate clear objectives, defined timelines, a comprehensive operational plan, and propose data that has relevance to the medical community.

Key Dates & Program Specifics:

  • Gilead will evaluate and award submissions following submission deadline.
  • LOI –
    • September 16, 2019: LOI submission window opens
    • October 11, 2019: LOI submission window closes

    LOI, PI CV and Overhead Policy forms should be submitted to using the templates provided below.

  • After submission window closes, Gilead will evaluate and rank all LOIs. Top ranked LOIs will be invited to submit a full application and additional instructions will be provided to the submitter.

Gilead approval of awards for research proposals depend on availability of funds and receipt of meritorious applications. Gilead anticipates that approximately 5 awards will be granted. No individual study may exceed $150,000 USD or equivalent sums. Awards shall be for research purposes only.

Questions about the PSC PACE Program announcement or application process should be submitted to your local Gilead Medical Scientist or Gilead reserves the right to approve or decline any application. Applications are reviewed by an internal review committee.